The present application relates to a preparation method for recycling inorganic salt in printing and dyeing wastewater and comprises the following process steps: S1, performing impurity removal, softening, COD removal and decoloration on reverse osmosis (RO) membrane concentrated water to obtain pretreated wastewater; S2, performing two-stage electrodialysis on the wastewater obtained in step S1: returning fresh water obtained in a first-stage electrodialysis desalination chamber to a front end of the RO process, and taking saline water obtained in a concentration chamber as raw water of a second-stage electrodialysis desalination chamber and a second-stage electrodialysis concentration chamber; and returning the fresh water obtained by the second-stage electrodialysis desalination chamber to the first-stage electrodialysis concentration chamber; and S3, dealkalizing the concentrated saline water obtained in the step S2 and then adjusting the pH value to obtain concentrated saline water capable of being reused for cloth dyeing in a printing and dyeing mill.

A paper-based micro-concentrator includes a bearing substrate, a fluid reservoir unit, a filter paper, an external electric field, an ion exchange membrane and a magnet. The fluid reservoir unit includes a first buffer solution tank and a second buffer solution tank, which are interval disposed on the bearing substrate. The filter paper is disposed on the bearing substrate, and two ends of the filter paper are respectively placed in the first buffer solution tank and the second buffer solution tank. The external electric field includes a cathode and an anode, which are respectively placed in the first buffer solution tank and the second buffer solution tank. The ion exchange membrane is disposed on the filter paper and close to the first buffer solution tank. The magnet is movably disposed under the bearing substrate.

A treatment system for performing a treatment on a patient may include a treatment fluid preparation device having a pump connected by a fluid channel to a reservoir of a source fluid, the pump conveying the source fluid from the reservoir, through a filter, and combining the source fluid with a concentrate by pumping the source fluid with the concentrate to form a treatment fluid in a batch container. The treatment fluid preparation device may have a controller that controls a heater, the pump, and a memory. The controller starts the heater to warm the treatment fluid in the batch container at a time that is responsive to the treatment time stored in the memory. The controller also detects a pressure property of the filter to determine its integrity and outputs an indication of a failed batch if the pressure property indicates the integrity of the filter is insufficient.

A treatment system for performing a treatment on a patient may include a treatment fluid preparation device having a pump connected by a fluid channel to a reservoir of a source fluid, the pump conveying the source fluid from the reservoir, through a filter, and combining the source fluid with a concentrate by pumping the source fluid with the concentrate to form a treatment fluid in a batch container. The treatment fluid preparation device may have a controller that controls a heater, the pump, and a memory. The controller starts the heater to warm the treatment fluid in the batch container at a time that is responsive to the treatment time stored in the memory. The controller also detects a pressure property of the filter to determine its integrity and outputs an indication of a failed batch if the pressure property indicates the integrity of the filter is insufficient.

Portable water conditioning systems include a water conditioner having a plurality of conditioning stages including, in a direction of flow of the water through the water conditioner, a reverse osmosis stage having a reverse osmosis membrane, and a deionizing stage. A first sensor is configured to detect a first condition of the water before the reverse osmosis stage and a second sensor configured to detect a second condition of the water after the reverse osmosis stage. The conditions each include (i) a level of total dissolved solids of the water and (ii) temperature of the water. A controller is in communication with the sensors and configured to determine of a percent of dissolved solids that are rejected by the reverse osmosis membrane based on the conditions when backpressure on the reverse osmosis stage is at a known state.

A process for purifying a liquid feedstock comprising a monoclonal antibody and impurities, the process comprising passing the liquid feedstock through an apparatus comprising at least two processing units, each such unit producing a product stream containing purified monoclonal antibody and optionally a waste stream comprising at least some of the impurities, wherein each unit comprises specified components (i) to (v) which include a multiple inlet flow-controller comprising two or more variable flow inlet valves for in situ production of a bioprocessing liquid by combining at least two liquids in a desired ratio. One of the units performs chromatography and another performs viral inactivation. The units may be essentially the same except for a device they contain, leading to advantages in terms of simplicity, cost and ease of operation, lower risk of operator error, easier maintenance and lower inventory of spare parts.

A process for producing pure lactic acid from a whey by-product rich in lactose and minerals, for example delactosed why permeate or concentrated whey permeate, is described. The method comprises upstream steps of neutralising the whey by-product with a basic metal hydroxide to form a precipitate comprising calcium and phosphate, and separating the precipitate from the whey by-product to provide a clarified whey by-product. The clarified whey by-product is fermentated by a bacterium capable of bioconversion of lactose to lactic acid to provide a fermentation broth containing a lactic acid salt. In the downstream steps, the fermentation broth is acidified to release lactic acid from the lactic acid salt, precipitate from the broth produced by acidification is removed, and the acidified fermentation broth is treated to recover pure lactic acid by removal of residual salts, and water, and optionally protein. The process of the invention produces lactic acid having a purity of 80-98% and an isomeric purity of >98% L-lactic acid using a process that employs upstream removal of divalent salts by chemical precipitation, bacterial fermentation of the demineralised substrate, and minimum downstream processing of the fermentation broth. The methods of the invention may also be employed with milk permeates.

A process for producing pure lactic acid from a whey by-product rich in lactose and minerals, for example delactosed why permeate or concentrated whey permeate, is described. The method comprises upstream steps of neutralising the whey by-product with a basic metal hydroxide to form a precipitate comprising calcium and phosphate, and separating the precipitate from the whey by-product to provide a clarified whey by-product. The clarified whey by-product is fermentated by a bacterium capable of bioconversion of lactose to lactic acid to provide a fermentation broth containing a lactic acid salt. In the downstream steps, the fermentation broth is acidified to release lactic acid from the lactic acid salt, precipitate from the broth produced by acidification is removed, and the acidified fermentation broth is treated to recover pure lactic acid by removal of residual salts, and water, and optionally protein. The process of the invention produces lactic acid having a purity of 80-98% and an isomeric purity of >98% L-lactic acid using a process that employs upstream removal of divalent salts by chemical precipitation, bacterial fermentation of the demineralised substrate, and minimum downstream processing of the fermentation broth. The methods of the invention may also be employed with milk permeates.

The present invention relates to processes for obtaining a highly concentrated antibody solution. In particular, to processes for obtaining a highly concentrated therapeutic antibody solution that may be used for highly concentrated therapeutic antibody formulations, e.g. suitable for subcutaneous administration.

The present invention relates to a dialysate regeneration method that reduces a urea concentration of a urea-containing aqueous solution, the method including a reverse osmosis process of obtaining, from the urea-containing aqueous solution, a concentrate having a higher urea concentration and a permeate having a lower urea concentration by using a reverse osmosis membrane element at an operating pressure of 0.5 MPa or more and 2.0 MPa or less, in which the urea concentration of the urea-containing aqueous solution is 0.5 g/L or more, the reverse osmosis membrane element includes a reverse osmosis membrane, and the reverse osmosis membrane has a pore diameter of 7.0 Å or less as measured by a positron annihilation lifetime measurement method.